USPTO Tells Fed. Circ. Ethicon's Stent IP Claims Are Invalid
The U.S. Patent and Trademark Office has defended a decision that found several claims in an Ethicon drug-eluting stent patent to be obvious, telling the Federal Circuit on Thursday the claimed...To view the full article, register now.
Already a subscriber? Click here to view full article